About FamiCord
FamiCord is a Healthcare company based in Leipzig (Germany). FamiCord is recognized as a leading European stem cell bank. It operates on a Managed Services and HealthTech model. FamiCord has completed 1 acquisition, including Smart Cells. FamiCord offers products and services including Stem Cells Banking and Cell Therapy Development. Its focus areas include Biotechnology and Stem Cell Therapy.
Company details
FamiCord is established as the foremost stem cell bank in Europe, specializing in the preservation of perinatal cells and tissues. Services are provided to families for umbilical cord blood and tissue storage, ensuring access to potential medical treatments. Additionally, comprehensive solutions in stem cell banking and cell therapy development are offered to business partners, including biotech companies and clinics. Operations span across multiple sectors such as regenerative medicine and biotechnology, with a network covering Europe, Asia, and Africa. Innovation and quality are prioritized to advance healthcare through research and clinical applications.
- Headquarters Leipzig, Germany
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website famicord.eu
- Investments & Acquisitions
Products & Services of FamiCord
FamiCord offers a comprehensive portfolio of products and services, including Stem Cells Banking and Cell Therapy Development.
Stem cells are collected and stored for families.
Cell therapy products are developed for medical use.
People of FamiCord
8 people are tracked at FamiCord (5 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Marcin Radziszewski | CFO | Leadership |
Magdalena Pietrasiuk | Director Of It, Business Excellence & Transformation Manager | Leadership |
Jakub Baran | CEO | Leadership |
Więcek Magdalena | Operations Director | Leadership |
Tomasz Baran | Chief Medical Oficer | Leadership |
Natalia MacHnio | Financial Analyst | Team |
Madalin-Georgian Radu | Finance Specialist | Team |
Anna Chądzyńska | HR Manager | Team |
Complete people profiles for FamiCord
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by FamiCord
FamiCord has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Smart Cells.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Umbilical cord blood stem cell storage services are provided. | smartcells.com | West Drayton, United Kingdom | 2000 | Aug 2021 | •••• |
Complete acquisition details for FamiCord
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as FamiCord (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about FamiCord
FamiCord is headquartered in Leipzig, Germany. It is registered at Leipzig, Saxony, Germany.
FamiCord is established as the foremost stem cell bank in Europe, specializing in the preservation of perinatal cells and tissues. Services are provided to families for umbilical cord blood and tissue storage, ensuring access to potential medical treatments. Additionally, comprehensive solutions in stem cell banking and cell therapy development are offered to business partners, including biotech companies and clinics. Operations span across multiple sectors such as regenerative medicine and biotechnology, with a network covering Europe, Asia, and Africa. Innovation and quality are prioritized to advance healthcare through research and clinical applications.
FamiCord offers Stem Cells Banking and Cell Therapy Development.
FamiCord has made 1 acquisition, including Smart Cells.